Calithera Biosciences, Inc. (CALA) financial statements (2020 and earlier)

Company profile

Business Address 343 OYSTER POINT BLVD #200
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6022774151141141
Cash and cash equivalents60227741516156
Short-term investments     8086
Receivables0223223
Other undisclosed current assets9911378788722
Total current assets:160137156121140145145
Noncurrent Assets
Property, plant and equipment1111122
Long-term investments and receivables      11
Long-term investments      11
Restricted cash and investments0000000
Other noncurrent assets0001111
Other undisclosed noncurrent assets7888   
Total noncurrent assets:91010112314
TOTAL ASSETS:169146166132143148159
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities207618151111
Accounts payable2112111
Accrued liabilities181116141010
Employee-related liabilities 43    
Other undisclosed current liabilities 1213    
Total current liabilities:20191918151111
Noncurrent Liabilities
Liabilities, other than long-term debt    111
Deferred revenue and credits11
Deferred rent credit    1  
Other undisclosed noncurrent liabilities7788   
Total noncurrent liabilities:7788111
Total liabilities:26262726161212
Stockholders' equity
Stockholders' equity attributable to parent142121139106127136147
Common stock0000000
Additional paid in capital428385383326323313305
Accumulated other comprehensive income (loss)000(0)(0)(0)(0)
Accumulated deficit(286)(264)(244)(220)(196)(177)(158)
Total stockholders' equity:142121139106127136147
TOTAL LIABILITIES AND EQUITY:169146166132143148159

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:      17
Operating expenses(22)(21)(25)(24)(20)(20)(21)
Operating loss:(22)(21)(25)(24)(20)(20)(4)
Nonoperating income
(Investment Income, Nonoperating)
0  00  
Other undisclosed income from continuing operations before equity method investments, income taxes2   2  
Loss before gain (loss) on sale of properties:(20)(21)(25)(24)(18)(20)(4)
Other undisclosed net income (loss)(2)  1(2)  
Net loss:(22)(21)(25)(24)(19)(20)(4)
Other undisclosed net income attributable to parent 11  11
Net loss available to common stockholders, diluted:(22)(20)(24)(24)(19)(19)(3)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(22)(21)(25)(24)(19)(20)(4)
Comprehensive loss:(22)(21)(25)(24)(19)(20)(4)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)110011
Comprehensive loss, net of tax, attributable to parent:(22)(20)(24)(24)(19)(19)(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: